Differential enhancement of melphalan cytotoxicity in tumor and normal tissue by fluosol-DA® and oxygen breathing

✍ Scribed by Beverly A. Teicher; Sylvia A. Holden; Christopher M. Rose

• Publisher: John Wiley and Sons
• Year: 1985
• Tongue: French
• Weight: 515 KB
• Volume: 36
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.2910360512

✦ Synopsis

The addition of Fluosol-DAB carbogen breathing to melphalan treatment of the FSa-IIC fibrosarcoma was assessed by tumor growth delay and cell survival assays. Melphalan (10 mg/kg) administered intraperitoneally (i.p.) was preceded by Fluosol-DA (0.3 ml) administered intravenously (Lv.) and followed by I hr of carbogen breathing; this resulted in a tumor growth delay of 9.5 f 1.4 days or an approximately 3-fold increase compared to melphalan alone. Melphalan produced about 1.7 logs of cell killing; neither carbogen breathing nor Fluosol-DA pretreatment altered the cell killing observed. There was a 10-fold increase in tumor-cell killing when Fluosol-DA was administered immediately prior to melphalan administration followed by carbogen breathing for 1 hr. Density gradient separation identified a population of denser FSa-IIC cells which showed increased sensitivity to melphalan after Fluosol-DA administration. There was no additional toxicity to bone marrow as measured by CFU-GM with the combination of melphalan/Fluosol-DA/Oz compared to melphalan alone.